Scienture Holdings, Inc.

Listed Company

SCNXCIK 0001382574NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$431.6K

Net Income

$-41.51M

Total Assets

—

Equity

—

Shares Out

40.63M

Op. Cash Flow

$-13.38M

SCNX$0.40−80.45% · past yearDBEQ Basic

Daily closing prices

Business

Scienture Holdings, Inc. is a specialty pharmaceutical company focused on commercializing and developing products for cardiovascular and central nervous system diseases. The company offers an FDA-approved oral liquid formulation of losartan (ArbliTM) for hypertension and has licensed naloxone nasal spray (REZENOPYTM) for opioid overdose treatment. Scienture operates a development pipeline of product candidates in migraine, thrombosis, pain management, and related disorders, with commercialization through U.S. direct sales and strategic partnerships internationally.

Summary from 10-K filed 2026-03-30

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	431,609	136,643	1	10	10
Cost of sales	100,127	130,638	1	5	5
Gross profit	331,482	6,005	49,030	6	5
Wage and salary expense	2	2	626,547	4	4
Professional fees	2	1	875,136	466,735	1
Accounting and legal expense	2	2	2	829,751	697,825
Technology expense	97,261	416,311	100,280	993,185	899,705
General and administrative	8	7	1	2	2
Research and development	2	2	—	—	—
Impairment loss	26	—	—	—	—
Total operating expenses	43	15	4	8	10
Operating loss	−43	−15	−4	−3	−5
Change in fair value of warrant liability	909,020	−182,982	−148,420	825,544	—
Change in fair value of derivative liability	2	180,383	—	—	—
Impairment of investment	—	−3	—	—	—
Loss on conversion of note payable	−53,446	—	—	—	—
Loss on disposition of subsidiaries	−288,204	—	—	—	—
Interest income	302,702	135,337	4,198	20,989	—
Loss on disposal of asset	—	−374,968	−3	2,200	—
Interest expense	−4	−1	−1	—	—
Total non-operating expense	−916,300	−4	−4	512,527	−23,590
Net loss from continuing operations	−44	−19	−8	—	—
Benefit / (provision) for income taxes	2	534,396	—	—	—
Net loss from continuing operations, net of tax	−42	−18	−8	−2	—
Net income from discontinued operations, net of tax	—	27	−9	−2	—
Net (loss) income	−42	9	−18	−3	−5
Basic	−2.7	−5.41	−11.1	−3.48	—
Diluted	−2.7	−5.41	−11.1	−3.47	—
Basic	—	8.09	−12.25	−2.67	—
Diluted	—	7.47	−3.93	−2.66	—
Basic (per share)	−2.7	2.69	−23.35	−6.15	—
Diluted (per share)	−2.7	2.48	−23.35	−6.13	−0.65
Basic (shares)	15	3	764,058	564,862	8
Diluted (shares)	15	4	2	566,609	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2022 2022-01-31
Cash and cash equivalents	7	308,096	—	—	—
Accounts receivable, net	731,328	11,106	—	629,921	—
Inventory	213,408	—	968	65,523	—
Prepaid expenses	262,278	4,560	50,724	104,461	—
Other receivables	—	4	1	—	—
Deferred offering costs	47,384	534,800	—	—	—
Current assets of discontinued operations	—	8,145	176,355	198,324	—
Total current assets	8	6	3	2	—
Property, plant and equipment, net	15,500	17,500	7,500	65,214	—
Deposits	—	22,039	10,531	49,029	—
Notes receivable	5	—	—	—	—
Interest receivable	250,000	—	—	—	—
Intangible assets, net	71	76	—	—	—
Goodwill	—	21	—	—	—
Operating lease right-of-use assets	23,360	201,433	191,216	1	642,887
Deferred tax asset	—	534,396	—	—	—
Total assets	84	105	13	4	—
Accounts payable	1	3	1	527,984	—
Accrued liabilities	657,034	1	160,214	271,230	—
Other current liabilities	—	5,441	67,831	67,517	—
Loan payable, related party	—	415,000	—	—	—
Convertible note, net of debt discount - current portion	—	2	—	—	—
Operating lease liability - current	24,137	63,334	32,595	196,872	—
Warrant liability	10,914	919,935	736,953	588,533	—
Development agreement liability - current portion	600,000	—	—	—	—
Current liabilities of discontinued operations	—	5,346	8	219,952	—
Total current liabilities	3	8	12	2	—
Convertible notes, net of debt discount	—	612,275	—	—	—
Derivative liability	—	2	—	—	—
Operating lease liability - net of current portion	—	156,469	176,909	887,035	—
Development agreement liability	285,000	1	—	—	—
Deferred tax liability	11	14	—	—	—
Total liabilities	14	26	12	3	—
Commitments and contingencies (Note 15)	—	—	—	—	—
Common stock, $0.00001 par value; 100,000,000 shares authorized; 40,630,815 and 8,750,582 shares issued and outstanding as of December 31, 2025 and 2024, respectively 1,015,000 and 0 shares unvested as of December 31, 2025 and 2024, respectively	406	87	9	6	—
Additional paid-in capital	151	118	34	20	—
Accumulated deficit	−81	−39	−33	−20	—
Total stockholders equity	70	79	542,353	763,136	—
Total liabilities and stockholders equity	84	105	13	4	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	2,000	2,000	19,375	13,486	7,351
Amortization of intangible assets	453,846	—	814,790	—	—
Change in fair value of warrant liability	−909,020	182,982	148,420	—	21,640
Loss on disposition of subsidiaries	214,486	—	—	—	—
Stock-based compensation	2	25,584	—	—	—
Common stock issued for services	4	5	257,772	254,106	181,163
Goodwill impairment	26	—	5	—	—
Amortization of debt discount	3	912,447	—	—	—
Amortization of right-of-use assets	35,935	51,361	215,665	181,218	131,558
Interest income	−250,000	—	—	—	—
Accounts receivable, net	−720,222	−11,106	−293,784	369,932	−789,587
Prepaid expenses and deposits	−193,023	34,656	38,367	335,066	−103,666
Inventory	−213,408	968	4	−51,737	825,127
Other receivables	−80,469	−3	−254,924	−875,250	1
Lease liability	−36,979	−51,587	−228,470	−164,618	−131,153
Accounts payable	−2	448,572	2	199,833	220,199
Accrued liabilities	−248,574	−44,616	58,692	−211,694	−13,819
Current liabilities	−5,441	−62,390	2,794	—	—
Net cash used in operating activities from continuing operations	−13	−13	4	−199,020	—
Net cash provided by (used in) operating activities from discontinued operations	2,799	−979,075	−6	−1	—
Net cash used in operating activities	−13	−14	−2	−2	−3
Cash received in acquisition	—	132,976	—	—	—
Acquisition of property and equipment	—	−12,000	—	—	−22,596
Investment in securities	—	−3	—	—	—
Net cash used in investing activities from continuing operations	—	−2	−344,454	749	—
Net cash provided by investing activities from discontinued operations	—	30	68,737	−428,594	—
Net cash provided by investing activities	—	28	−275,717	−427,845	−22,596
Repayment of contingent liability	—	−1	−1	−716,964	—
Proceeds from loan payable, related party	116,000	150,000	—	—	—
Repayment of loan payable, related party	−531,000	—	—	—	−225,000
Proceeds from issuance of convertible notes, net of issuance costs	—	3	—	—	—
Proceeds from convertible notes	4	—	—	—	—
Repayment of convertible notes	−9	—	—	—	—
Gross proceeds from issuance of common stock	26	—	—	130,918	—
Repayment of development liability	−400,000	—	—	—	—
Cash dividends paid	—	−15	—	—	—
Proceeds from exercise of warrants	—	16,567	1,622	875	15,001
Proceeds from exercise of options	—	9,840	—	—	1,821
Net cash provided by (used in) financing activities from continuing operations	20	−13	2	239,829	—
Net cash used in financing activities from discontinued operations	—	−5,000	−500,000	−275,000	—
Net cash provided by (used in) financing activities	20	−13	1	−35,171	−208,178
Net change in cash	6	307,782	−1	−2	−3
Cash paid for interest	—	—	733,694	336,206	28,337
Cash paid for taxes	—	—	—	—	—
Conversion of note payable into common stock	411,000	—	—	—	—
Equity line of commitment shares issued as offering costs	2	534,800	—	—	—
Issuance of note receivable in exchange for other receivables	5	—	—	—	—
Issuance of shares pursuant to Merger	—	79	—	—	—
Assets acquired in connection with Merger	—	194,554	—	—	—
Liabilities assumed in connection with Merger	—	6	—	—	—
Insurance premium financed	—	198,245	306,152	220,354	—
Issuance of common shares in connection with converible debenture	—	420,200	—	—	—
Deferred offering costs	—	69,444	—	—	—
Derivative liability recognized in connection with issuance of convertible note	—	2	—	—	—
Warrants issued with convertible note	—	71,332	—	—	—
Common stock issued for convertible note settlement	189,673	—	—	—	—
Common stock issued for convertible note extension	175,250	—	—	—	—
Accretion of original issue discount on Treasury Bills	20,625	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Scienture Holdings, Inc.'s CIK number?

Scienture Holdings, Inc.'s SEC CIK number is 0001382574 (1382574). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Scienture Holdings, Inc.'s SEC filings?

All of Scienture Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Scienture Holdings, Inc. last report earnings?

Scienture Holdings, Inc. (SCNX) most recently filed an earnings 8-K with the SEC on May 22, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-025062). This is Scienture Holdings, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Scienture Holdings, Inc.'s most recent earnings 8-K?

Scienture Holdings, Inc.'s latest earnings 8-K (Item 2.02) was filed May 22, 2026 under accession 0001493152-26-025062. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Scienture Holdings, Inc.'s latest earnings 8-K →
Look up any company's CIK number →